Latham-Led Cancer Treatment Co. Wraps Up $175M Financing
Cancer-focused biotechnology company Affini-T Therapeutics, led by Latham, said Tuesday that it has amassed $175 million in an oversubscribed financing round co-led by Vida Ventures and the impact investing unit of...To view the full article, register now.
Already a subscriber? Click here to view full article